PEG showed no clear difference in adverse events compared with lactulose (moderate certainty).
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
The review found no eligible studies for this question.
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).